Navigation Links
Einstein researcher receives American Cancer Society Medal of Honor
Date:11/9/2010

November 5, 2010 (BRONX, NY) Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.

Insights into how normal body cells support tumor growth have led the way to a new wave of research and the development of therapeutics specifically targeting the support cells in the body that can aid in tumor development. Dr. Pollard's research has found that when macrophages are removed from the tumor microenvironment, the risk of cancer progressing to malignancy is reduced and its spread from the primary tumor site to distant sites lessens.

"I think that one of the major components of the therapeutic arsenal as we go forward will be to combine chemo-therapeutic drugs with drugs that target macrophages so that they can no longer support the tumor's ability to be malignant," said Dr. Pollard. "Further it gives another opportunity for therapy by using vaccination against tumor antigens combined with altering macrophages from tumor promoting to tumor rejecting. It gives us another prong in the attack on cancer."

Dr. Pollard is deputy director of the Albert Einstein Cancer Center, director of the Center for Study of Reproductive Biology and Women's Health and the Louis Goldstein Swan Chair in Women's Cancer Research at Einstein. He is also professor in the departments of developmental and molecular biology and obstetrics & gynecology and women's health at Einstein and Montefiore Medical Center.

This award from the American Cancer Society, the nation's leading voluntary
'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Einstein receives $30 million to study protein form and function
2. Einstein designated an NIH Center of Excellence for aging research
3. Einstein receives $4 million to test HPV microbicide
4. Einstein researcher awarded prestigious cancer research grant
5. Einstein-Montefiore research tackles childhood obesity in the Bronx
6. Einstein researchers discover 2 new ways to kill TB
7. Einstein receives high-risk/high-reward cancer research funding
8. Einstein to develop anti-HIV drug delivery system
9. Einstein scientists move closer to a safer anthrax vaccine
10. Einstein researchers devise a fast and sensitive way to detect ricin
11. NIH funds research center for womens reproductive health at Einstein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... University College of Dentistry (NYUCD) research team has found the ... sapiens out of Africa to Asia. , The ... comprehensive care at NYUCD, discovered that Streptoccocus mutans, a bacterium ... hosts in a clear line that can be traced back ...
... is highly effective in preventing death from lung cancer ... disease by up to 70%. In addition, new research ... increases the risk of dying from lung cancer in ... the continuing popularity of cigarette smoking across large parts ...
... care unit (ICU) already are seriously ill, so the last ... that as many as 25 percent of all patients admitted ... can be fatal. , Ventilator-associated pneumonia is a major cause ... this infection can add $40,000 to costs and double the ...
Cached Biology News:'Ancestral eve' was mother of all tooth decay 2Quitting smoking reduces risk of lung cancer mortality by 70 percent 2Bacteria from patient's dental plaque causes ventilator-associated pneumonia 2
(Date:3/4/2015)... , March 4, 2015 The UPMC ... its 2015 Fellows in the Emerging Leaders in Biosecurity ... future leaders in the field of biosecurity, UPMC has ... from a wide array of backgrounds, including biological science, ... sector. "With the vision and support ...
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ... new report "Biomarkers - Technologies, Markets and ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:3/4/2015)... March 04, 2015 PRC Clinical, ... the San Francisco Bay Area, will exhibit and present ... Conference 2015 on March 25th and 26th in ... build relationships with Israeli life science companies seeking to ... The company’s services span all phases of human trials, ...
(Date:3/4/2015)... NEWTOWN, Pa. , March 4, 2015 ... trials services and technology provider, today announced ... and 10 countries convened at its annual ... Spain to discuss the use ... development challenges. BioClinica,s eClinical technologies include: the ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3
... of Healthcare Products to ... and Bleeding Disorders, OTTAWA, April 3, 2008 ... Blood Services, and Hema-Quebec, have each awarded,the company ... P (Antihemophilic factor / von Willebrand Factor,Complex [Human], ...
... the Anniversary by Ringing The Closing Bell(R) at ... the ... Edwards,Lifesciences Corporation (NYSE: EW ), a world leader in ... of partnering with clinicians to develop life-saving,innovations. To celebrate its five ...
... Anadys,Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today ... Conference on Wednesday, April 9, 2008,at 3:00 p.m. EDT ... the St.,Regis Hotel in New York City., Steve ... Inc., will present an overview of Anadys and an ...
Cached Biology Technology:CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 2CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 3CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 4CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 5CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 6CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 7CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 8Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 2Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 3Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference 2
... MitoPT kit is used in conjunction with your ... and induce apoptosis according to your existing procedure ... a negative control). Once you have induced apoptosis ... to each population and incubate the cells for ...
... The biolistic PDS-1000 He system ... gas to accelerate micron-size nucleic acid-coated ... necessary to transfect cells, tissues, or ... the cell surface. The system includes ...
Sf21 Insect Cells (Frozen) in Max-XP Medium...
... The MyCycler thermal cycler system is ... applications. This system includes the MyCycler personal ... module for use with 0.2 ml tubes ... options, and both algorithm and block modes ...
Biology Products: